Biogen Idec Ma Inc.

Biogen Ma Inc.

William Sisk

Nels Eric Pederson

Holly Prentice

Graham K Farrington

The invention is based, at least in part, on the finding that a dimeric version of a BBB-transmigrating antibody (e.g., the TMEM30A (CDC-50A) binding antibody, FC5) was found to greatly enhance transport across the BBB as compared to monovalent FC5 V. The invention provides, inter alia, molecules that increase transport of pharmacologically active agents across the blood brain barrier, methods for increasing transport across the blood brain barrier, and methods of treatment of disorders or diseases having a neurological component.

Enhancement of transport of therapeutic molecules across the blood brain barrier

A method of producing a secreted neublastin polypeptide using a heterologous signal sequence is disclosed. The secreted neublastin does not contain a neublastin pro sequence.

Neublastin expression constructs

The disclosure provides an expression cassette and a vector comprising the cassette for expression of a polynucleotide. The expression cassette includes a promoter/enhancer, an intervening region, and a polyadenylation signal domain. Expression systems and methods of using the expression cassette and vector are also provided.

Growing community of inventors

Boxborough, MA, United States of America

William Sisk